How Targeted Nutrition Can Empower Health Outcomes

Redefining Health in the Age of GLP-1

The rise of GLP-1 receptor agonists has catalyzed one of the fastest paradigm shifts in modern health and nutrition. What began as a therapeutic solution for type 2 diabetes has quickly become a broader movement that is reshaping how millions of people eat, supplement, and manage their wellness.

Nearly 15 million Americans, representing about 10% of U.S. adults, now use GLP-1 medications, and more than half of U.S. adults are clinically eligible for these treatments. Consumer awareness has accelerated in parallel, with approximately 45% of global consumers familiar with GLP-1 drugs and 41% indicating willingness to use them for weight management. Their impact extends far beyond endocrinology, influencing food culture, consumer behavior, and supplement formulation at an unprecedented scale.

Mechanisms and Physiological Effects

GLP-1 receptor agonists work through three primary actions:

• Delaying gastric emptying
• Increasing insulin secretion
• Suppressing appetite

While clinically effective, these mechanisms influence nutrient absorption, gastrointestinal comfort, and hydration status. Key observations from recent literature include:

• Loss of lean body mass can account for 20-40% of total weight loss.
• Gastrointestinal effects such as nausea, constipation, and delayed transit are common.
• Thirst suppression and reduced fluid intake increase the risk of dehydration.
• Weight regain occurs in up to two-thirds of individuals within one year of discontinuation.

A New Class of Supplement Consumers

GLP-1 users can be grouped into five categories: Metabolic Maintenance Users, Comorbidity-Managed Patients, Performance-Driven Adopters, Lifestyle-Oriented Users, and Medically-Directed Intermittent Users.

They engage with GLP-1 therapy for prevention, disease management, or aesthetic goals. We explore each group’s motivators, physiological needs, emotional drivers, and treatment-related effects later in the article to better understand how GLP-1 users are redefining supplement innovation and nutritional science. Collectively, they represent a new class of consumers—motivated, medically engaged, and compliance-driven:

• 83% find products marketed as “GLP-1 supportive” appealing
• 81% are willing to pay more for them
• 74% are open to trying new delivery formats

These consumers value science-based, targeted support formulations that complement GLP-1 pharmacology without interference. Key priorities include maintaining gastrointestinal comfort, muscle integrity, and metabolic balance.

Evolving Use and Emerging Needs

As clinical applications expand, GLP-1 use continues to reveal new nutritional and physiological considerations. Beyond appetite regulation and glycemic control, research points to broader effects on nutrient absorption, hydration, and tissue health. These findings are guiding how both pharmaceutical and nutraceutical developers approach formulation design.

Current evidence identifies concerns related to digestive function, hydration balance, micronutrient depletion, ocular health, and dermal integrity, the latter often discussed in consumer media as “Ozempic face.” These areas of impact create measurable opportunities for innovation that support users throughout every stage of their GLP-1 journey.

Formulations that improve tolerance in the short term, sustain nutrient and hydration balance through ongoing use, and aid in post-treatment recovery represent immediate business potential. Addressing these needs positions supplement manufacturers to play an active role in long-term metabolic wellness.

As awareness grows, so does public interest. Search activity for GLP-1 therapies, their benefits, and related products continues to increase, reflecting a population that is both clinically engaged and nutritionally underserved. This rising demand signals the beginning of a new growth phase for evidence-based, GLP-1-aligned innovation.

As GLP-1 adoption accelerates, market activity continues to reflect sustained public interest. Global search data from 2020 through 2025 shows a sharp and persistent rise in GLP-1-related terms, paralleling prescription growth and the expansion of adjacent categories such as functional foods and metabolic supplements.

This growing awareness has shortened the window for category differentiation.

 Oct 2020 – Oct 2025

There is no time like now

The window for establishing category leadership in this space is projected to be 12-18 months as major supplement brands begin to enter this space.

Companies that can connect validated science with patient-centric delivery and consumer trust will define this next phase of innovation.

With demand at its peak, the next step is understanding GLP-1 users, their physiological needs, treatment goals, and adherence patterns. The next section profiles these user groups and highlights ingredient approaches that align with their nutritional and therapeutic requirements.

Metabolic Maintenance Users

Proactive patients focused on prevention and sustained metabolic health. They integrate GLP-1 therapy into structured wellness routines emphasizing glucose control and nutrient efficiency.
Therapy considerations and treatment-associated issues: Extended gastric emptying, reduced micronutrient absorption, and altered gut microbiota.
Formulation implications: Enzyme systems to improve digestion, probiotics for microbiome stability, and excipients that enhance bioavailability in low-caloric states.

Comorbidity-Managed Patients

Clinically monitored users treating obesity, diabetes, or cardiovascular risk factors under medical supervision. Adherence and tolerance are primary concerns.
Therapy considerations and treatment-associated issues: Nausea, reflux, dehydration, and irregular absorption of co-administered actives.
Formulation implications: Simethicone for gastric comfort, moisture-controlled carriers such as GalenIQ® or MannoGems®, and formats that simplify multi-drug regimens.

Performance-Driven Adopters

Highly engaged individuals using GLP-1s to accelerate body-composition change or metabolic optimization. They combine therapy with fitness and dietary regimens.
Therapy considerations and treatment-associated issues: Lean-mass loss, fatigue from caloric restriction, and reduced recovery capacity.
Formulation implications: Protein-compatible excipients, lipid systems using MCT oil for sustained energy, and enzyme complexes supporting amino-acid uptake.

Lifestyle-Oriented Users

Appearance-focused consumers incorporating GLP-1s into broader wellness or beauty routines. Convenience, tolerability, and product experience influence adherence.
Therapy considerations and treatment-associated issues: Early satiety, dehydration, and concerns related to dermal elasticity or dullness.
Formulation implications: Hydrating electrolyte systems, collagen-stabilized carriers, and palatable oral dispersibles or ready-to-mix powders that reinforce routine use.

Medically-Directed Passive Users

Patients prescribed GLP-1s for clinical need but demonstrating limited intrinsic motivation or inconsistent adherence. Engagement depends on ease of use and perceived comfort.
Therapy considerations and treatment-associated issues: Low persistence, intolerance to GI side effects, and minimal self-management behavior.
Formulation implications: Simple, low-burden delivery systems such as chewables or ODTs, nitrosamine-safe excipients, and enzyme-based comfort formulations that encourage continuation.

Emerging Supplement Innovations for GLP-1 Support

As GLP-1 therapeutics continue to reshape the metabolic and nutritional landscape, companion formulations must address the physiological gaps created by delayed gastric emptying, appetite suppression, and altered digestive function. Several ingredient classes are showing distinct potential for targeted nutritional intervention:

• Digestive Comfort and Tolerance: Simethicone serves as a key anti-foaming agent to reduce gastric bloating and discomfort caused by slowed gastrointestinal transit. When combined with optimized tablet excipients such as GalenIQ or MannoGems, and Actimask supports uniform dispersion and improved palatability in chewable and orodispersible formats. Furthermore

  • Check out this case study on chewable anti-gas tablets with high activity that is beneficial for these side effects

• Protein and Nutrient Utilization:Enzyme systems such as Bromelain, Pepsin, Papain, Amylase, and Lipase enhance macronutrient digestion and bioavailability under conditions of reduced enzymatic activity and food volume intake. These systems can be paired with MCT Oil as a readily metabolized lipid source to support satiety, muscle preservation, and sustained energy production during caloric restriction.

• Microbiome and Gut Health: Probiotics and postbiotic stabilization systems aid in maintaining microbial balance disrupted by slower GI transit, improving nutrient absorption and immune resilience. Their incorporation into moisture-protected carriers such as GalenIQ allows stable, viable delivery across variable gastric conditions. Explore more on the technical write-up here. 

• Structural and tissue support: Collagen hydrolysates, Chondroitin sulfate, and Hyaluronic acid aid in maintaining dermal integrity and joint function, aligning with aesthetic and musculoskeletal needs identified among long-term GLP-1 users.

• Immune and microbiome health: Colostrum, Lactoferrin, and Beta-glucan help preserve immune resilience and microbial balance affected by slower gastric transit.

• Safety and Stability Considerations: nitrosamine-safe excipients and directly compressible fillers such as Advantose® and Pharmaburst™ enable stable, patient-compliant dosage forms for daily use.

Collectively, these formulation technologies provide a comprehensive toolkit for addressing the immediate, ongoing, and post-treatment needs of GLP-1 users. They form the foundation for next-generation companion products that maintain comfort, protect nutrient status, and extend the value of GLP-1 therapies beyond pharmacological treatment.

These ingredient platforms target the key physiological and compliance challenges of GLP-1 therapy, including digestive discomfort, nutrient depletion, and treatment fatigue. They also enable patient-friendly dosage forms that improve tolerability, support consistent use, and promote long-term adherence. Validated companion products built on these technologies establish a clear pathway to enhance gastrointestinal comfort, optimize nutrient absorption, and aid recovery following treatment discontinuation.

The Future of Supplementation in GLP-1 Care

As more than 100 GLP-1–related therapies enter R&D pipelines globally , the opportunity extends beyond product formulation—it involves redefining how consumers nourish metabolic health in tandem with pharmaceutical interventions. Ingredient suppliers play a leading role in shaping this next frontier, where validated nutrition science and precision supplementation can help sustain results, adherence, and quality of life.